L
Laurent Poirot
Researcher at Royal Holloway, University of London
Publications - 80
Citations - 3208
Laurent Poirot is an academic researcher from Royal Holloway, University of London. The author has contributed to research in topics: Chimeric antigen receptor & Immunotherapy. The author has an hindex of 23, co-authored 66 publications receiving 2484 citations.
Papers
More filters
Patent
Methods for engineering allogeneic and highly active t cell for immunotheraphy
Roman Galetto,Agnès Gouble,Stephanie Grosse,Cécile Schiffer-Mannioui,Laurent Poirot,Andrew M. Scharenberg,Julianne Smith +6 more
TL;DR: This paper used rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells.
Patent
Method of engineering multi-input signal sensitive t cell for immunotherapy
TL;DR: In this article, a method to engineer an immune cell for immunotherapy using chimeric antigen receptors (CARs) was described. But the method was not applied to T-cells, which were used in cancer treatments.
Journal ArticleDOI
Optimized tuning of TALEN specificity using non-conventional RVDs
Alexandre Juillerat,Coline Pessereau,Gwendoline Dubois,Valérie Guyot,Alan Maréchal,Julien Valton,Fayza Daboussi,Laurent Poirot,Aymeric Duclert,Philippe Duchateau +9 more
TL;DR: By implementing new non-conventional RVDs (ncRVDs) that possess novel intrinsic targeting specificity features, it is demonstrated in living cells the possibility to efficiently promote TALEN-mediated processing of a target in the HBB locus and alleviate undesired off-site cleavage.
Patent
Method for in situ inhibition of regulatory t cells
TL;DR: In this article, the authors present a method for the preparation and use of engineered T-cells for immunotherapy, particularly for cancer and bacterial or viral infections, which opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial and viral infections.
Journal ArticleDOI
Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.
Mohit Sachdeva,Brian W. Busser,Sonal Temburni,Billal Jahangiri,Anne-Sophie Gautron,Alan Maréchal,Alexandre Juillerat,Alan N. Williams,Stéphane Depil,Philippe Duchateau,Laurent Poirot,Julien Valton +11 more
TL;DR: The authors improve CAR T cell antitumor responses by simultaneously targeting a CAR to TCR locus and IL-12 to PD1 locus, placing the transgenes under a naturally regulated transcriptional network while disrupting unwanted signals.